OmniAb (OABI) Stock Price, News & Analysis

Company Overview

OmniAb, Inc. is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases.

The company’s technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets. OmniAb also provides related discovery capabilities and works with partners to identify and advance antibody-based therapeutics, including conventional monoclonal antibodies and other engineered antibody formats.

OmniAb was established as an independent public company in 2022 after being separated from Ligand Pharmaceuticals. The company serves biotechnology and pharmaceutical partners internationally through research collaborations, licensing arrangements and other strategic relationships. Its business model is centered on enabling partner drug programs rather than primarily commercializing its own portfolio of marketed medicines.

Key Stats

• Today's Range: $4.99 to $5.36
• 50-Day Range: $3.95 to $5.28
• 52-Week Range: $1.30 to $5.43
• Volume: 1.14 million shs
• Average Volume: 1.41 million shs
• Market Capitalization: $749.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Moderate Buy

OmniAb Stock Analysis - MarketRank™

OmniAb scored higher than 47% of companies evaluated by MarketBeat, and ranked 578th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OmniAb has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

OmniAb has a consensus price target of $11.50, representing about 122.0% upside from its current price of $5.18.

Amount of Analyst Coverage

OmniAb has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OmniAb are expected to grow in the coming year, from ($0.34) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OmniAb is -15.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OmniAb is -15.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OmniAb has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.54% of the float of OmniAb has been sold short.

Short Interest Ratio / Days to Cover

OmniAb has a short interest ratio ("days to cover") of 6.67.

Change versus previous month

Short interest in OmniAb has recently increased by 4.22%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OmniAb does not currently pay a dividend.

Dividend Growth

OmniAb does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.49

News Sentiment

OmniAb has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for OmniAb this week, compared to 3 articles on an average week.

Search Interest

Only 1 people have searched for OABI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added OmniAb to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OmniAb insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of OmniAb is held by insiders.

Percentage Held by Institutions

72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/30/2026
• Today: 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:OABI
• CIK: 1846253
• Web: www.omniab.com
• Phone: 510-250-7800
• Fax: N/A
• Employees: 89
• Year Founded: 2012

Price Target and Rating

• Average Price Target for OmniAb: $11.50
• High Price Target: $12.00
• Low Price Target: $11.00
• Potential Upside/Downside: +122.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.78 million
• Net Margins: -108.11%
• Pretax Margin: -109.12%
• Return on Equity: -16.74%
• Return on Assets: -14.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.21
• Quick Ratio: 4.80

Sales & Book Value

• Annual Sales: $18.67 million
• Price / Sales: 40.17
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.72 per share
• Price / Book: 3.01

Miscellaneous

• Outstanding Shares: 144,780,000
• Free Float: 130,594,000
• Market Cap: $749.96 million
• Optionable: Optionable
• Beta: 0.60